Zenith Capital Corp. ZHCLF

Zenith Capital Corp., a biotechnology investment company, develops bromodomain (BET) inhibitors for the treatment of cancer and other disorders with unmet medical needs in Canada. The company’s lead compound ZEN-3694, which is in Phase 2b clinical trial for the treatment of metastatic castration resistant prostate cancer, as well as for NUT carcinoma, solid tumors, breast and metastatic cancer, ovarian and colorectal cancer, lung and pancreatic cancer, and malignant peripheral nerve sheath tumors. It has collaborations with the National Cancer Institute, Astellas Pharma, Newsoara Biopharma Co., University of California San Francisco, Merck & Co., Memorial Sloan Kettering Cancer Center, University of Pittsburgh Medical Center – Hillman Cancer Center, Bristol Myers Squibb, Dana-Farber - Harvard Cancer Center, Eli Lilly and Company, University of Texas MD Anderson Cancer Center, Yale University Cancer Center, U.S. Army Medical Research and Development Command, Sidney Kimmel Comprehensive Cancer Center, University of Alabama Birmingham, and Pfizer. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. Zenith Capital Corp. was incorporated in 2013 and is headquartered in Calgary, Canada.